Boston, Mass. – February 6, 2019 – Decibel Therapeutics will showcase capabilities across its inner ear-focused drug discovery and development platform at the 42nd annual mid-winter meeting of the Association for Research in Otolaryngology (ARO) from February 9-13, 2019. The data to be presented will demonstrate new insights on the delivery of medicines to the inner ear through multiple modalities, including gene therapy and biologics, as well as the development of biomarkers, assays and tools to address cochlear synaptopathy and other disorders.

“This last year has been transformative for Decibel,” said Michael Su, Ph.D., Decibel’s chief scientific officer. “Not only have we advanced two compounds for the prevention of hearing loss into Phase I clinical studies, but we’ve also strengthened our discovery and delivery capabilities in support of our early stage pipeline programs in monogenic hearing loss, tinnitus and balance. We’re looking forward to sharing this broader suite of capabilities with our colleagues at ARO.”

The Decibel team will have a total of 11 presentations during the conference:

Podium Presentations

Presidential Symposium 6 | Refinement of Age-related Hearing Loss Patient Populations and Targeted Treatments

  • Presenter: Michael Su, Ph.D.
  • Session Title: Presidential Symposium
  • Date & Time: Saturday, February 9, 10:50a.m.

PD 42 | Vgf Expression is a Biomarker of NTF3 Target Engagement in Mouse Spiral Ganglion Neurons In Vitro and In Vivo

  • Presenter: Joseph Burns, Ph.D.
  • Session Title: Intracochlear Drug Delivery & Biomarkers
  • Date & Time: Sunday, February 10, 2:15p.m.

PD 45 | Restoration of Hearing in Tmc1-Deficient Mice Depends on Early and Well-Regulated Gene Delivery

  • Presenter: Adam Palermo, Ph.D.
  • Session Title: Intracochlear Drug Delivery & Biomarkers
  • Date & Time: Sunday, February 10, 3:00p.m.

PD 43 | Dual AAV Vectors for Delivery of Large Genes

  • Presenter: Theresa Abell, M.S.
  • Session Title: Intracochlear Drug Delivery & Biomarkers
  • Date & Time: Sunday, February 10, 2:30p.m.

Poster Presentations

PS 273 | Unbiased Classification of Audiometric Phenotypes in the NHANES Database

PS 469 | In Vitro Characterization of Different AAV-Ntf3s for Proof of Concept In Vivo Studies

PS 695 | A Single Cell Transcriptomic Characterization of the Stria Vascularis and Lateral Wall from the Adult Mouse Cochlea

PS 707 | Development of Robust In Vitro and Ex Vivo Assays to Support Drug Discovery Programs 

PS 708 | Distribution and Retention of Neurotrophin-3 in Cochlea

PS 709 | Functional Improvement and Target Engagement in Mouse Model of Synaptopathy Following Sustained Exposure via AAV8-Ntf3 Delivery

PS 710 | Tropism of Engineered Serotypes in Adult Rodent Cochlea: Towards Translationally Relevant Vectors

For further detail on Decibel’s presence at the conference, please visit the Association for Research in Otolaryngology website at

About Decibel Therapeutics, Inc.

Decibel Therapeutics, a clinical-stage biotechnology company, has established the world’s first comprehensive drug discovery, development, and translational research platform for hearing and balance disorders. Decibel’s lead therapeutic candidates, DB-020 and DB-041, are designed to prevent hearing loss resulting from cisplatin and aminoglycoside antibiotics, respectively. Decibel is also advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibel is headquartered in Boston, Mass. For more information about Decibel Therapeutics, please visit or follow @DecibelTx on Twitter.

Media Contact

Sara Green, Ten Bridge Communications
(617) 233-1714